Want to see DRMA full AI Analyst Report?
DRMA Stock Chart & Stats
$2.14
-$0.06(-4.41%)
At close: 4:00 PM EST
$2.14
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$1.10 - $8.00
Previous CloseN/A
Volume28.34K
Average Volume (3M)249.42K
Market Cap
$5.39M
Enterprise Value-$6.04M
Total Cash (Recent Filing)$6.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.31
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.84
Forecast
1Y Price Target
$4.00Price Target Upside86.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt reduces fixed financial obligations and lowers bankruptcy risk, giving management flexibility to fund clinical programs through equity, partnerships, or grants. For a pre-revenue biotech, this structural strength preserves options over the next several quarters.
Narrowing Losses / Improved Operating ScaleThe meaningful reduction in net losses from 2024 to TTM signals improved cost discipline and operational efficiency. Sustained loss narrowing can extend runway, reduce near-term financing needs, and increase ability to focus capital on pivotal clinical milestones.
Enhanced Financing And Incentive FlexibilityShareholder approval to expand equity incentives and authorize warrant actions provides durable capital-raising flexibility and aligns employee incentives. This structural governance change increases ability to secure funding and retain talent needed to advance trials.
Bears Say
Pre-revenue BusinessZero reported revenue means the company lacks commercial cash flows and remains wholly dependent on external financing to sustain operations. This structural limitation raises dilution risk and makes progress contingent on successful clinical outcomes or partner deals.
Persistent Cash BurnContinued negative operating and free cash flow of roughly -$8.3M TTM shows the company is consuming capital to fund development. Even with improvement, sustained burn pressures runway and forces recurring financing or partnerships, constraining strategic flexibility.
Small Asset Base And Limited RunwayA modest asset base (~$7.5M) and limited equity reduce the firm's capacity to absorb clinical trial costs or unexpected expenses. Structurally, this increases likelihood of near-term dilution or reliance on partnerships, limiting independent strategic maneuvering.
Dermata Therapeutics News
DRMA FAQ
What was Dermata Therapeutics’s price range in the past 12 months?
Dermata Therapeutics lowest stock price was $1.10 and its highest was $8.00 in the past 12 months.
What is Dermata Therapeutics’s market cap?
Dermata Therapeutics’s market cap is $5.39M.
When is Dermata Therapeutics’s upcoming earnings report date?
Dermata Therapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.
How were Dermata Therapeutics’s earnings last quarter?
Dermata Therapeutics released its earnings results on May 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $0.05.
Is Dermata Therapeutics overvalued?
According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued.
Does Dermata Therapeutics pay dividends?
Dermata Therapeutics does not currently pay dividends.
What is Dermata Therapeutics’s EPS estimate?
Dermata Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Dermata Therapeutics have?
Dermata Therapeutics has 4,022,143 shares outstanding.
What happened to Dermata Therapeutics’s price movement after its last earnings report?
Dermata Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went up 3.361%.
Which hedge fund is a major shareholder of Dermata Therapeutics?
Currently, no hedge funds are holding shares in DRMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dermata Therapeutics
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
DRMA Stock 12 Month Forecast
Average Price Target
$4.00
▲(86.92% Upside)
Technical Analysis
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
30.83% Insiders
0.56% Mutual Funds
0.54% Other Institutional Investors
68.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---